Moomoo AI 已提取核心信息
Arcutis Biotherapeutics, a commercial-stage biopharmaceutical company, has announced the offering of 15,789,474 shares of its common stock. The shares are listed on the Nasdaq Global Select Market under the symbol 'ARQT.' The offering price per share is set at $9.50, aiming to raise approximately $150 million before expenses. Underwriters have been granted a 30-day option to purchase up to an additional 2,368,421 shares. The offering is expected to close on or about March 4, 2024. Morgan Stanley, TD Cowen, Guggenheim Securities, Mizuho, and Needham & Company are managing the offering. The proceeds are intended for funding the continued commercialization, development, and approval of Arcutis' multiple programs, including potential launches in atopic dermatitis and scalp psoriasis, and for general corporate purposes.
Arcutis Biotherapeutics, a commercial-stage biopharmaceutical company, has announced the offering of 15,789,474 shares of its common stock. The shares are listed on the Nasdaq Global Select Market under the symbol 'ARQT.' The offering price per share is set at $9.50, aiming to raise approximately $150 million before expenses. Underwriters have been granted a 30-day option to purchase up to an additional 2,368,421 shares. The offering is expected to close on or about March 4, 2024. Morgan Stanley, TD Cowen, Guggenheim Securities, Mizuho, and Needham & Company are managing the offering. The proceeds are intended for funding the continued commercialization, development, and approval of Arcutis' multiple programs, including potential launches in atopic dermatitis and scalp psoriasis, and for general corporate purposes.
处于商业阶段的生物制药公司Arcutis Biotherapeutics宣布发行15,789,474股普通股。这些股票在纳斯达克全球精选市场上市，股票代码为 “ARQT”。每股发行价定为9.50美元，目标是在支出前筹集约1.5亿美元。承销商已获得30天的期权，可以额外购买最多2,368,421股股票。此次发行预计将于2024年3月4日左右结束。摩根士丹利、道明考恩、古根海姆证券、瑞穗和Needham & Company正在管理此次发行。所得款项旨在为Arcutis多个项目的持续商业化、开发和批准提供资金，包括可能在特应性皮炎和头皮牛皮癣领域推出，以及用于一般公司用途。
处于商业阶段的生物制药公司Arcutis Biotherapeutics宣布发行15,789,474股普通股。这些股票在纳斯达克全球精选市场上市，股票代码为 “ARQT”。每股发行价定为9.50美元，目标是在支出前筹集约1.5亿美元。承销商已获得30天的期权，可以额外购买最多2,368,421股股票。此次发行预计将于2024年3月4日左右结束。摩根士丹利、道明考恩、古根海姆证券、瑞穗和Needham & Company正在管理此次发行。所得款项旨在为Arcutis多个项目的持续商业化、开发和批准提供资金，包括可能在特应性皮炎和头皮牛皮癣领域推出，以及用于一般公司用途。
有用
没用